Allergan: raises FY targets
(CercleFinance.com) - Alongside the announcement of its results, Allergan has raised its annual targets (non-GAAP data), looking for EPS of at least 16.
55 dollars (vs. at least 16.36 dollars previously), with revenues of between 15.1 billion and 15.4 billion dollars (against between 15 billion and 15.3 billion dollars previously).
Over the first three months of 2019, the pharmaceutical company recorded adjusted EPS that is up 1.3% at 3.79 dollars, which is almost 25 cents higher than the consensus.
At 3.6 billion, sales were down 2%, mainly due to certain losses in exclusivity and product divestments in 2018, albeit partially offset by the strength of key products such as Botox. Vraylar and Juvederm.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
55 dollars (vs. at least 16.36 dollars previously), with revenues of between 15.1 billion and 15.4 billion dollars (against between 15 billion and 15.3 billion dollars previously).
Over the first three months of 2019, the pharmaceutical company recorded adjusted EPS that is up 1.3% at 3.79 dollars, which is almost 25 cents higher than the consensus.
At 3.6 billion, sales were down 2%, mainly due to certain losses in exclusivity and product divestments in 2018, albeit partially offset by the strength of key products such as Botox. Vraylar and Juvederm.
Copyright (c) 2019 CercleFinance.com. All rights reserved.